GD2T<sub>IF</sub> cells as a platform for single-dose and long-term delivery of biologics.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40883321.
- Also identified by DOI 10.1038/s41467-025-63427-w and PMC identifier 12397235.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The efficacy of biologics, such as peptide and protein drugs, is often limited by their short half-lives in vivo, necessitating repeated infusions to maintain therapeutic effects. Here, we demonstrate that long-lived CAR T cells can be leveraged as a versatile platform for long-term delivery of biologics. Our recent findings show that the depletion of BCOR and ZC3H12A induces GD2 CAR T cells into an immortal-like and functional state, which we have termed GD2T<sub>IF</sub> cells. These GD2T<sub>IF</sub> cells expanded in immunocompetent mice without the need for chemotherapeutic conditioning and persisted as a polyclonal population, safely and almost indefinitely. In leptin-deficient ob/ob mice, a single infusion of GD2T<sub>IF</sub> cells producing leptin effectively and durably corrected leptin deficiency. Furthermore, a single infusion of GD2T<sub>IF</sub> cells secreting GLP-1 prevented obesity and diabetes in mice fed on a high-fat diet. The longevity, safety, and adaptability of GD2T<sub>IF</sub> cells suggest their potential as a general platform for long-term delivery of biologics, offering durable therapeutic efficacy with a single infusion.
Medical subject headings
- Biological Products
- T-Lymphocytes
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive